The advantage is preservation of anatomical mostly structures and reduced morbidity to the patient. The aggressive treatment is done considering ��neoplastic nature�� of KOT and includes peripheral ostectomy, chemical curettage, or enbloc resection. It is mostly recommended for large lesions, recurrent cases and syndromic patients. Decompression has also been used to treat KOTs, which have aggressive behavior and having tendency to recur.[14] Few authors recommend ��site-and size-based�� approach for the treatment of KOT. Dammer et al.[24] have suggested conservative approach for small KOTs (maximum 1 cm in diameter) near alveolar process, and radical excision for larger lesions near the base of the skull that has invaded soft tissue. On the contrary, Forsell and coworkers have reported that the size of the lesion does not affect the recurrence rate.

[25] Future modalities Due to the recent advances and thus determination of molecular basis of this entity, a new novel methodology concentrating on molecular aspects has been devised. The Hh pathway can be blocked at different levels, and Hh inhibitors could serve as attractive antitumor agents.[26] According to some studies, cyclopamine, a plant-based steroidal alkaloid, blocks activation of SHh pathway caused by oncogenic mutation.[27] Other studies also show antagonists of SHh signaling factors could effectively treat KOT.[28] CONCLUSION So the whole process of classifying and renaming the odontogenic cysts and tumors continues as the understanding of these lesions takes a giant leap in its stride.

So what is there in a name? A rose is a rose, whatever you call it. This concept is certainly not correct when it comes to OKC/KOT. There is as yet no international consensus, either on the question of the cyst’s neoplastic nature, or on a name change. A famous oral surgeon ��Gordon Hardman�� was quoted saying ��We always knew some cysts recurred so the patient came to have them curetted out every 5-10 years. So what, we never had to give them separate names.��[6] This attitude of the surgeons overlooking the multiple recurrences has always been suppressing the concept of reclassifying these lesions (favorite work of the pathologists). The controversies over the nature of OKC are infact a reflection of our limited knowledge of this fascinating entity.[14] ��A rose is a rose is not a rose,�� when it implies to OKC/KOT.

The term ��odontogenic keratocyst�� is so engraved in the literature only time can tell us whether the term ��keratocystic odontogenic tumor�� can substitute this term successfully or not. Recent advances in genetic and molecular understanding have led to eventually eliminate the need for aggressive treatment modalities. This article is in AV-951 a hope to suggest that the naming of OKC as a benign tumor allows the surgeon to tailor their treatment aptly. Footnotes Source of Support: Nil Conflict of Interest: None declared.